SGCG抗体;SGCG Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse liver tissue lysate, Primary antibody: P13257(SGCG Antibody) at dilution 1/400, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P13257(SGCG Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The SGCG antibody targets the gamma-sarcoglycan protein encoded by the SGCG gene, which is crucial for maintaining muscle membrane integrity. Gamma-sarcoglycan is a component of the dystrophin-associated glycoprotein complex (DGC) in skeletal and cardiac muscle. This complex stabilizes the sarcolemma during contraction and links the cytoskeleton to the extracellular matrix. Mutations in SGCG cause limb-girdle muscular dystrophy type 2C (LGMD2C), a recessive disorder characterized by progressive muscle weakness and wasting.

SGCG antibodies are essential tools in research and diagnostics. They enable detection of gamma-sarcoglycan expression in tissues, aiding in the confirmation of LGMD2C diagnoses through immunohistochemistry, Western blotting, or immunofluorescence. Reduced or absent gamma-sarcoglycan levels in muscle biopsies are hallmarks of the disease. Additionally, these antibodies help study disease mechanisms, such as disrupted DGC assembly and compromised membrane stability.

In therapeutic research, SGCG antibodies assist in evaluating gene therapy or protein replacement strategies aiming to restore functional gamma-sarcoglycan. They also serve as biomarkers in preclinical trials to assess treatment efficacy. Commercial SGCG antibodies vary in specificity; validation via knockout controls is critical. Overall, SGCG antibodies bridge basic research, clinical diagnostics, and emerging therapies for sarcoglycanopathies.